February 3, 2021
Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock
February 1, 2021
Revolution Medicines Announces Proposed Public Offering of Common Stock
January 5, 2021
Revolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare Conference
November 12, 2020
Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress
October 24, 2020
Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers
October 12, 2020
Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors
September 16, 2020
Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors
September 9, 2020
Revolution Medicines to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 8, 2020
Revolution Medicines to Participate in 2nd Annual RAS-Targeted Drug Development Conference
August 10, 2020
Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Progress